<DOC>
	<DOCNO>NCT00392834</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , rituximab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . Drugs use chemotherapy work different way stop growth cancer cell , either kill cell stop divide . Giving rituximab together combination chemotherapy may kill cancer cell . PURPOSE : This phase II trial study well give rituximab together combination chemotherapy work treat patient newly diagnose , HIV-associated Burkitt 's lymphoma .</brief_summary>
	<brief_title>Rituximab Combination Chemotherapy Treating Patients With Newly Diagnosed , HIV-Associated Burkitt 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine efficacy rituximab , cyclophosphamide , vincristine , doxorubicin hydrochloride , high-dose methotrexate ( R-CODOX-M ) alone alternate rituximab ifosfamide , etoposide phosphate , high-dose cytarabine ( IVAC ) intrathecal CNS prophylaxis patient newly diagnose , previously untreated , HIV-associated Burkitt 's lymphoma atypical Burkitt 's lymphoma . - Determine safety regimen patient . Secondary - Evaluate downstream effector apoptosis mechanisms chemotherapy resistance prognosis perform exploratory analysis relationship treatment effect . - Evaluate multi-drug resistance gene expression mechanism chemotherapy resistance prognosis perform exploratory analysis relationship treatment effect . - Confirm use flow cytometry identification occult leptomeningeal disease determine whether abnormal flow cytometry predictive CNS cytology negative malignant cell . - Determine biologic prognostic significance Epstein-Barr virus ( EBV ) -positive Burkitt 's lymphoma highly active antiretroviral therapy era perform exploratory analysis relationship treatment effect . - Compare genotyping patient HIV-associated Burkitt 's lymphoma patient HIV-negative determine whether uniform genetic profile whether case like diffuse large B-cell lymphoma . - Determine EBV detection cerebrospinal fluid diagnosis predictive leptomeningeal disease . OUTLINE : This prospective , multicenter study . Patients stratify accord risk category ( low-risk v high-risk ) . Patients low-risk disease receive 3 course R-CODOX-M chemotherapy describe . Patients high-risk disease receive 4 alternating course R-CODOX-M/IVAC chemotherapy describe A/B/A/B sequence . * Courses repeat every 21-28 day absence disease progression unacceptable toxicity . NOTE : *In patient present anasarca , pleural effusion , ascites , methotrexate pool cause difficulty clearance ; case , treatment may give reverse sequence : B/A/B/A . - Regimen A ( R-CODOX-M chemotherapy ) : Patients receive rituximab** IV doxorubicin hydrochloride IV 15 minute day 1 , cyclophosphamide IV 30-60 minute day 1 2 , pegfilgrastim subcutaneously ( SC ) day 3 , vincristine IV day 1 8 , high-dose methotrexate IV 2-4 hour day 15 , leucovorin calcium IV begin 24 hour start methotrexate continue every 6 hour methotrexate level le 50 nmol/L . Patients receive CNS prophylaxis comprise methotrexate intrathecally ( IT ) , cytarabine IT , hydrocortisone IT day 1 . Patients high-risk disease receive additional dose cytarabine IT day 3 . Patients also receive filgrastim ( G-CSF ) SC daily day 3-9 . Once methotrexate level drop 50 nmol/L , patient resume G-CSF SC daily begin approximately day 18 continue blood count recover . - Regimen B ( rituximab IVAC chemotherapy ) : Patients receive rituximab** IV day 1 , ifosfamide IV continuously etoposide IV continuously 24 hour day 1-5 , high-dose cytarabine IV 1-3 hour twice daily day 1-2 . Patients receive CNS prophylaxis comprise methotrexate IT hydrocortisone IT day 5 . Patients also receive pegfilgrastim SC 24-48 hour completion chemotherapy OR G-CSF SC begin day 6 continue blood count recover . Patients CNS involvement ( leptomeningeal and/or intraparenchymal ) diagnosis receive CNS prophylaxis . Instead , patient receive combination sequential liposomal cytarabine methotrexate IT via Ommaya reservoir day 1 every 14 day tolerate completion systemic chemotherapy . NOTE : **Rituximab may give 3 day chemotherapy course anytime course 3 ( low-risk disease ) 4 ( high-risk disease ) total dos . Patients undergo blood cerebrospinal fluid collection tumor biopsy periodically study treatment correlative study prognostic biomarkers predictive survival ( e.g. , c-flip protein expression ; p53 mutation [ immunohistochemistry ( IHC ) ] ; multidrug resistance gene expression [ IHC ] ; Epstein-Barr virus tumor DNA cerebrospinal fluid [ polymerase chain reaction ] ) ; genotyping Burkitt 's lymphoma ; flow cytometry tool ( stain ) detect occult positivity leptomeningeal disease Burkitt 's lymphoma . After completion study treatment , patient follow every 4 month least 2 year . PROJECTED ACCRUAL : A total 34 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm Burkitt 's lymphoma ( BL ) new WHO 2009 criterion Bcell lymphoma unclassified ( feature intermediate difuse large Bcell lymphoma BL ) Any stage disease Newly diagnose disease Meets 1 follow criterion disease risk : Lowrisk disease , define 1 following : Stage I single focus disease &lt; 10 cm AND normal lactate dehydrogenase ( LDH ) level Totally resected intraabdominal disease AND normal LDH post surgery Highrisk disease , define meeting criterion lowrisk disease Measurable nonmeasurable disease HIVpositive confirm enzymelinked immunosorbent assay Western blot OR measurable HIV viral load No visceral Kaposi 's sarcoma PATIENT CHARACTERISTICS : Karnofsky performance status 40100 % Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception LVEF ≥ 50 % MUGA echocardiogram Creatinine ≤ 1.5 mg/dL OR creatinine clearance ≥ 60 mL/min Absolute neutrophil count ≥ 1,000/mm³ Platelet count ≥ 50,000/mm³ ( unless relate lymphoma ) * Direct bilirubin ≤ 2.0 mg/dL OR total bilirubin ≤ 3.5 mg/dL AND direct bilirubin normal ( elevated bilirubin secondary antiretroviral therapy ) AST ALT ≤ 3 time upper limit normal No malignancy within past 5 year except curatively treat cutaneous basal cell squamous cell carcinoma , carcinoma situ cervix , cutaneous Kaposi 's sarcoma No medical illness unrelated nonHodgkin 's lymphoma , include follow : Uncontrolled infection ( include opportunistic infection ) Chronic renal insufficiency Myocardial infarction within past 6 month Unstable angina Cardiac arrhythmia chronic atrial fibrillation Patients active hepatitis B infection eligible provide receive concurrent dual antiviral therapy NOTE : *Patients bone marrow involvement eligible irrespective blood count PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior therapy disease except 1 follow : Seven consecutive day steroids alone combination nonCHOP regimen necessary patient stabilization ( e.g. , cyclophosphamide steroid steroid normalization diseaserelated hyperbilirubinemia ) One course CHOP fractionate CHOP ( e.g . CODOX ) without rituximab No epoetin alfa filgrastim ( GCSF ) within 24 hour study chemotherapy No concurrent zidovudine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>stage I adult Burkitt lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>contiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>AIDS-related peripheral/systemic lymphoma</keyword>
</DOC>